Peroxitech Therapeutics Secures Seed Funding to Advance New Treatment of Acute Lung Injury

Peroxitech Therapeutics Secures Seed Funding to Advance New Treatment of Acute Lung Injury

Peroxitech’s lead compound, PIP-2, works to target the cytokine storm buildup in the lungs that leads to respiratory failure, regardless of etiology. More specifically, PIP-2 targets a newly discovered earlier pathway for cytokine storm activation. The company has successfully conducted studies showing prevention of moderate to severe ALI when PIP-2 is dosed prophylactically, and near complete rescue and restoration of lung function when dosed 12 hours after the onset of ALI. PIP 2 also demonstrated breakthrough survival data for improved survival and outcomes in ALI caused by COVID-19 infection.

About PIP-2

About Peroxitech Therapeutics, Inc.

“We are excited to announce our collaboration with Peroxitech to address the unmet need for developing drugs to treat and prevent acute lung injury,” said Chris Garabedian, Founder, Chairman and Chief Executive Officer of Xontogeny. “Developing treatments for acute lung injury is more pressing than ever, as it is the leading cause of death following COVID-19 infections. The Xontogeny team has enjoyed working with the Peroxitech team, and we are aligned on the key milestones that we plan to achieve with this seed investment.”

Infections and trauma, including from COVID-19 infection, activates the cytokine storm cascade, which causes lung inflammation and results in oxidative stress and cell death, resulting in ALI. Pathophysiology of ALI is essentially the same no matter the etiology, causing alteration of the lung alveolar capillary barrier leading to lung edema and respiratory failure. Patients with ALI spend an average of 32 days in the hospital, with 20 of those days spent under mechanical ventilation. Mortality in patients experiencing ALI has been shown in studies to be as high as 40%, and ALI is the leading cause of death in COVID-19 cases.

The Board of Directors will be comprised of Thomas Han CEO of Peroxitech, Chris Garabedian, Chairman & CEO of Xontogeny, and Fred Callori, SVP of Corporate Development of Xontogeny.

There are an estimated 190,000 cases of ALI in the US each year; incidences of ALI are expected to increase both nationally and globally as COVID-19 infections lead to additional cases of ALI. Peroxitech’s lead product, PIP-2 is delivered into the lungs to prevent the cytokine storm cascade to treat and prevent ALI. PIP-2 helps to target cytokine build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis, regardless of etiology. More specifically, PIP-2 targets peroxiredoxin 6 (Prdx6), a newly discovered pathway in the cytokine storm cascade process. As current medical response consists primarily of lung protective ventilation, PIP-2 could offer a breakthrough modality to prevent and rescue patients with ALI.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Peroxitech Therapeutics products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Peroxitech Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding options as well as the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders. For more information visit www.xontogeny.com.

About Xontogeny, LLC

Peroxitech Therapeutics is a biopharmaceutical company focused on treating acute lung injury (ALI) through its development of a novel peptide to target a newly-identified pathway of disease presentation. Their lead compound, PIP-2, works to eliminate the reactive oxygen species (ROS) build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis characteristic of acute lung injury, regardless of etiology. For more information, please visit: www.peroxitech.com.

The News Highlights

  • Peroxitech Therapeutics Secures Seed Funding to Advance New Treatment of Acute Lung Injury
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
During the Xbox and Bethesda Games Showcase, The Outer Worlds 2 was unveiled

During the Xbox and Bethesda Games Showcase, The Outer Worlds 2 was unveiled

The Outer Worlds 2 has been announced during the Xbox and Bethesda Showcase. Prepare to journey to the edges of the galaxy once more Obsidian Entertainment ...
Best Cheap Bose Speaker Deals for June 2021

Best Cheap Bose Speaker Deals for June 2021

Looking for more Bose ear candy? Check out these headphone deals as well. If you’re after a new speaker and you want something solid and with excellent ...
Money Talks: The Mom and the College Student Who Shared Stimulus Checks

Money Talks: The Mom and the College Student Who Shared Stimulus Checks

Kai: I spend too much of my life online, so I heard about it on Twitter pretty much as soon as it happened. I was excited, because I looked through and saw ...
Swarmshop Breach: Hackers Leak Hacker Data

Swarmshop Breach: Hackers Leak Hacker Data

According to Group-IB researchers, hackers leaked data from Swarmshop, known as “a medium-sized” neighborhood “store for stolen personal and payment ...
Requiem will be released in 2022 and will be available on Xbox Game Pass

Requiem will be released in 2022 and will be available on Xbox Game Pass

A Plague Tale: Innocence came out two years ago and became something of a cult classic. With a dark and frightening atmosphere, the action/puzzle game hovers ...
Wedding Vendors Overwhelmed by  News Boom Due to Lifting Restrictions

Wedding Vendors Overwhelmed by News Boom Due to Lifting Restrictions

Source www.wtvr.com You should also consider an off-month. The summer and fall see the highest demand. “Maybe push up your timeline a little bit because I’ve ...
Dark Reading |  Security Protect the business

Dark Reading | Security Protect the business

Read the full WSJ report for more information. Attackers stole emails, phone numbers, and addresses belonging to delivery customers in South Korea and ...
Everything Announced at E3 by Xbox and Bethesda

Everything Announced at E3 by Xbox and Bethesda

Specifically, the showcase shared details on 30 titles, 27 of which will be available on Xbox Game Pass. From the announcement of new Bethesda franchise ...
Bitcoin and the rich |  Financial Times

Bitcoin and the rich | Financial Times

Quick on the draw: a decade on from first investing, Sandra Ro has made a substantial fortune from bitcoin © Pascal Perich But bitcoin still divides opinion. ...
All about Apple Beats Studio Buds TWS Earbuds

Introduction of Beats Studio Buds is said to be imminent

According to FrontPageTech.com, also known by fans of initialism as FPT, the Beats Studio Buds (listed as Beats Studio Buds: True Wireless Noise Canceling ...
Show next
Compsmag - Latest News from tech, business and health
Logo